Oct 16,2018

CytoReason: New machine learning driven findings uncover new cellular players in tumor micro-environment that might point the way to improved immunotherapy for refractory melanoma patients

CytoReason presented groundbreaking findings at the American Association for Cancer Research Special AI Conference, highlighting potential new cellular players in the tumor microenvironment that could impact immunotherapy for refractory melanoma patients. Using their unique machine learning model of the immune system, the study identified adipocytes as potentially involved in the response to nivolumab in patients who failed to respond to ipilimumab. These preliminary findings suggest a regulatory role for adipocytes and reveal undisclosed potential targets for future therapies.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 28,2024 TOP STORY

Sidekick Health presents impactful real-world data from their digital oncology program at ASCO 2024

Sidekick Health will present real-world data from its digital oncology program at ASCO 2024 on June 1st. This app-based program supports cancer patients in self-managing their health, focusing on mental resilience, nutrition, stress, medication reminders, and symptom tracking. Key findings from a retrospective analysis of the program showed significant improvements in quality of life and symptom severity for highly engaged users. Statistically significant enhancements in energy, sleep, and reductions in fatigue and nausea were observed. Additionally, each week in the program correlated with a 3.5% decrease in overall symptoms, including stress and nausea. The program, offered free to US-based cancer patients, demonstrated that digital self-management can effectively improve patient outcomes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 28,2024

PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study

The Precision Cancer Consortium (PCC), in collaboration with Massive Bio, has unveiled promising results from a study that tested Massive Bio’s AI system for improving the matching process for clinical trials involving cancer patients. This study included major pharmaceutical companies such as AstraZeneca, Bayer, and Roche. Traditionally, manually screening patients for cancer trials is time-consuming, limiting patient access to suitable trials and negatively impacting enrollment rates. Massive Bio’s AI system, enhanced with GPT-4, integrates Next-Generation Sequencing (NGS) data to refine trial matching. The study analyzed data from 5,707 cancer patients, finding that only 27% had accessible NGS results. The AI system was able to match 690 unique patients to at least one trial, resulting in 1,254 patient-trial pairs, nearly doubling the efficiency of the matching process. The AI system achieved nearly 100% efficiency, significantly reducing manual labor and saving an estimated 19,500 hours.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 22,2024

Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study

The study aimed to assess glucose metrics and identify predictors of glycemic outcomes in children and adolescents during their first year using the MiniMed 780G system. The longitudinal, real-world study involved 368 children and adolescents with type 1 diabetes (T1D) who began using SmartGuard technology from June 2020 to June 2022. Data were collected at baseline (15-day run-in period), 2 weeks after activating automatic mode, and every 3 months thereafter. The impact of various factors on glycemic outcomes after one year of using MiniMed 780G was evaluated. After one year, time in range (TIR) was significantly higher than at baseline (75.3% vs. 62.8%). The mean glycated hemoglobin (HbA1c) was lower (6.9% vs. 7.4% in the previous year). Higher TIR was linked to fewer automatic correction boluses, fewer SmartGuard exits, and longer time in automatic mode. The study demonstrates the sustained effectiveness of MiniMed 780G in improving glycemic outcomes for youth with T1D. The findings suggest that even those with low initial therapeutic engagement can benefit from SmartGuard technology.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
May 22,2024

Study Finds Spark Direct Effective in Improving Mood Among Adults With Depression

Big Health announced the successful results of a randomized controlled trial showing that their digital CBT program for depression, Spark Direct, significantly improves mood and quality of life in adults. The study, involving 61 adults with moderate to moderately-severe depression, highlighted Spark's ease of use (95% satisfaction) and its effectiveness in enhancing motivation and providing actionable coping strategies. Participants using Spark experienced mood improvements 2.5 times greater than those in the control group, with benefits sustained for an additional five weeks post-program. Quality of life improvements for Spark users were nearly double that of the control group. Spark Direct, which utilizes cognitive-behavioral techniques, covers mental health education, behavioral activation, mindfulness, and long-term skill maintenance.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
May 03,2024

Innosphere starts paediatric clinical trial for Novostim ADHD device

Innosphere Engineering has initiated a clinical trial for its Novostim 2 device, aimed at treating pediatric ADHD. The trial, involving children aged 7-12, will use transcranial random noise stimulation (tRNS) to enhance brain activity. Conducted over two months, the study includes 10 days of 20-minute treatments where children play a digital engagement game. Data from this trial will support FDA clearance. Novostim 2 is a non-invasive device that subtly enhances brain activity to improve attention.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
May 16,2024

GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

GlucoTrack, Inc. has announced successful results from the first 30 days of a 60-day preclinical study for its implantable continuous glucose monitor, which measures glucose levels in the epidural space. The study showed that the sensor accurately tracked blood glucose levels and a commercially available subcutaneous CGM in animals, with no complications observed. This device aims to simplify disease management for patients with painful diabetic neuropathy. The study will continue to assess the long-term performance of the sensor. If approved, this technology could significantly benefit the millions of people with diabetes affected by neuropathy. The 60-day long-term study is ongoing, with periodic glucose tolerance testing to compare the performance of the Glucotrack epidural sensor performance against blood glucose and subcutaneous CGM.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 07,2024

Researchers Use Foundation Models to Discover New Cancer Imaging Biomarkers

Researchers at Mass General Brigham have utilized foundation models, similar to those powering tools like ChatGPT, to uncover new cancer imaging biomarkers. These biomarkers could revolutionize the identification of patterns in radiological images, leading to advancements in early cancer detection and treatment. Their foundation model, trained on a vast dataset of abnormal radiologic scans, successfully predicted anatomical site, malignancy, and prognosis across various use cases and cohorts. Notably, the model's effectiveness persisted even in scenarios with limited data availability, outperforming existing methods in specialized tasks. Published in Nature Machine Intelligence, the study highlights the potential for more accurate and efficient investigations in image biomarker research.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 10,2024

Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies

This clinical study aimed to characterize glucose levels during uncomplicated pregnancies, defined as pregnancies with normal A1c levels in early pregnancy and without complications like large-for-gestational-age birth or gestational diabetes. A total of 413 pregnant individuals wore Dexcom G6 continuous glucose monitoring (CGM) devices throughout their pregnancy. Results showed stable glucose levels throughout all trimesters, with an overall mean glucose level of 98 mg/dL. Most time was spent within the target range of 63-120 mg/dL, with rare instances of levels above 140 mg/dL. Post-prandial peak glucose was 126 mg/dL on average. Higher mean glucose levels were associated with higher body mass index (BMI). These findings provide insight into glucose levels during uncomplicated pregnancies and can inform treatment targets for pregnant individuals.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 26,2024

NOVEL STUDY TO ASSESS WAVE HEALTH FOR STEM CELL TRANSPLANT PATIENTS DELIVERS PROMISING RESULTS AND VALUABLE REAL-WORLD DATA

Interim findings from a study by Treatment Technologies & Insights (TTI) and Wilmot Cancer Institute reveal promising results for Wave Health's mobile app. The study is designed to assess the feasibility and usability of a customized version of the Wave Health mobile app for self-monitoring and symptom reporting by adult recipients of Allogeneic Stem Cell Transplantation (SCT) at risk for Chronic Graft-versus-host Disease (cGVHD). Participants engage with the app over a four-week period, tracking daily activities, mood, and symptoms, and completing weekly symptom reviews. 88% of participants used the app weekly, indicating feasibility, while 89% found it easy to use, highlighting its potential to enhance cGVHD symptom monitoring in stem cell transplant recipients.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY